Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (17)	12/20/1999 2:15:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 598

TD: Thanks! It's going to be soooooooooo much fun to see the impact that these newcomers may have on the sorting of valuations. They have instantly created an "impoverished" class of companies that are nonetheless big-science. >> Note, however, that the statement refers to more than one binding site. Sounds like there is still a long way to go before they identify the key binding site(s) and hence which series to optimize. << As an immunologist, I can help. First, you compare one monoclonal STAT6 with a bunch of others. After you determine which differences cluster to isotypes, you do simple genetic tests to eliminate allotypes. The remaining differences will distinguish the CDR, and, presto!, you've got your key binding site. Sheeeeesh. You chemists. Rick